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Aim of database: The main aim of the Danish National Acute Leukemia Registry (DNLR) was 
to obtain information about the epidemiology of the hematologic cancers acute myeloid leukemia 
(AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).
Study population: The registry was established in January 2000 by the Danish Acute Leukemia 
Group and has been expanded over the years. It includes adult AML patients diagnosed in 
Denmark since 2000, ALL patients diagnosed since 2005, and MDS patients diagnosed since 
2010. The coverage of leukemia patients exceeds 99%, and the coverage of MDS patients is 
currently 90%.
Main variables and descriptive data: Approximately, 250 AML patients, 25 ALL patients, 
and 230 MDS patients are registered in the DNLR every year. In January 2015, the registry 
included detailed patient characteristics, disease characteristics, treatment characteristics, and 
outcome data on more than 3,500 AML, 300 ALL, and 1,100 MDS patients. Many of the included 
prognostic variables have been found to be of high quality including positive predictive values 
and completeness exceeding 90%. These variables have been used in prognostic observational 
studies in the last few years. To ensure this high coverage, completeness, and quality of data, 
linkage to the Danish Civil Registration System and the Danish National Registry of Patients, 
and several programmed data entry checks are used.
Conclusion: The completeness and positive predictive values of the leukemia data have been 
found to be high. In recent years, the DNLR has shown to be an important high-quality resource 
for clinical prognostic research.
Keywords: data quality, registries, population-based, acute myeloid leukemia, acute lympho-
blastic leukemia, myelodysplastic syndrome
Introduction
The Danish National Acute Leukemia Registry (DNLR) includes adult patients with 
acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodys-
plastic syndrome (MDS).
The aim of the registry is to gain insight into the epidemiology of these cancers, 
to evaluate treatment responses, to compare results between geographical regions 
of Denmark, and, through research, to identify prognostic and predictive factors for 
outcome. One ultimate aim is to improve the quality of treatment and care for acute 
leukemia and MDS patients.
The DNLR has been a part of the Danish Hematological Database since 2005. Report-
ing of patient data for the aforementioned diagnoses is mandatory, and obtainment of 
patient consent is not required. Financial support for the registry depends directly on 
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registration completeness and coverage. The steering committee 
for the registry is required to publish an annual report based on 
specific quality indicators. The indicators are data complete-
ness; 30-, 180-day, 1-, 3-, and 5-year mortality; time from diag-
nosis to treatment initiation (TTT); and proportions of patients 
achieving a complete remission (CR), included in clinical trials, 
and with a cytogenetic evaluation at diagnosis.1
Study population
Acute leukemias are highly aggressive blood cancers, arising 
from hematopoietic stem cells or committed progenitor cells. 
The acute leukemia is classified as myeloid or lymphoblastic 
leukemia (AML or ALL) depending on origin. Both AML 
and ALL are characterized by rapid outgrowth of leukemic 
cells that disrupt the production of normal blood cells. This 
enhances the risks of anemia, life-threatening infections, 
and bleeding complications. Prognostic factors, types of 
treatment, and prognosis differ between the two subtypes. In 
AML patients, the three most important prognostic factors 
are age, cytogenetic alterations, and performance status (PS) 
(Figure 1A and B).2 The survival in younger ALL patients 
has improved over time, but despite the development of 
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new treatment regimens for AML, survival rates for AML 
patients have not changed significantly over more than a 
decade (Figure 1C and D).
MDS also arises from myeloid stem cells or committed 
progenitor cells, and is associated with ineffective production 
and dysfunction of the normal blood cells. The spectrum 
of MDS ranges from light anemia to affecting all the three 
hematopoietic cell lines.2 Treatment principles vary from 
supportive care only (use of blood products, antibiotics, and 
growth factors), to low-dose chemotherapy, and to intensive 
AML-like remission-inducing chemotherapy in patients 
with increasing blast counts progressing to AML. Overall 
survival and time to progression to AML can be estimated 
using the original or revised International Prognostic Scor-
ing System.3
The Danish population, ∼5.7 million people,4 is guar-
anteed free access to tax-supported medical care provided 
by the public health care system. Approximately, 250 new 
cases of AML, 25–35 of ALL, and 200–250 of MDS are 
diagnosed annually. The treatment takes place within ten 
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Figure 1 Survival in Danish AML and ALL patients registered in the Danish National Acute Leukemia Registry.
Notes: (A) Survival in AML patients, by age group; (B) survival in AML patients, by functional status (wHO performance status score); (C) survival in ALL patients, by years since 
diagnosis (n=159); and (D) survival in AML patients (diagnosed between 2005 and 2010), by years since diagnosis (n=2,398). Data from the Annual Leukemia Report, 2010.4
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; wHO, world Health Organization.
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specialized hematological departments. Six of these depart-
ments offer intensive therapy to AML and ALL patients, 
though treatment of Philadelphia chromosome-negative 
ALL patients younger than 45 years is centralized at three 
centers. MDS patients are treated at all ten departments. 
Two centers perform allogeneic hematopoietic stem cell 
transplantation in ALL, AML, and MDS patients.
The Danish Society of Hematology established the DNLR 
in 2000. Since then, all adult (.15 years) AML patients diag-
nosed in Denmark have been recorded. Since January 2005, 
adult patients diagnosed with ALL have also been included. 
In 2010, a separate registry for newly diagnosed cases of 
MDS was established. Before then, only cases of advanced 
MDS that were treated using AML protocols were recorded 
in the leukemia registry.1 Since the beginning of registra-
tion, more than 3,500 AML patients, 300 ALL patients, and 
1,100 MDS patients diagnosed before January 1, 2015 have 
been registered in the DNLR. The continuing registration 
annually expands the registry with ∼250 AML patients, 25 
ALL patients, and 230 MDS. 
Main variables
The DNLR uses standardized web-based registration forms 
to collect data and the system allows programmed data entry 
checks. Lists of patients newly diagnosed with AML, ALL, 
or MDS in the Danish National Registry of Patients (DNRP)5 
are sent to each hematological department for a confirmation 
of the diagnosis. If correct, additional data are entered in the 
registry. For these purposes, medical records including patho-
logy records (Patobank)6 are used. To ensure high coverage 
and completeness of data, the registry is linked to the Danish 
Civil Registration System7 and the DNRP every 3 months.
For AML and ALL patients, up to four registration forms 
are completed during the disease course of each patient 
Table 1 Data recorded on registration forms used by the Danish National Acute Leukemia Registry
Registration form and time of registration Variables
Acute leukemia (AML, ALL)  
Registration form
Name, civil registration (CPR) number, and demographic data
At diagnosis Diagnosis according to wHO (2008)/iCD-10
From 2011, the cytogenetic details are included in a separate registration 
form
Date of diagnosis and date of first visit to a health care unit
Prior hematological or solid cancer (specified, if present)
Prior treatment with radio- or chemotherapy
wHO Performance Status Score (wHO PS)
Height and body weight
Presence of extramedullary leukemia (EML) (specified, if present)
FAB-type, blast percentage in the blood and bone marrow
Results of cytogenetic evaluation (conventional cytogenetics and FiSH)
Leukocyte and platelet counts and level of lactate dehydrogenase (LDH)
Planned chemotherapy (yes/no)
Date of initiated treatment/decision of “no treatment”
Treatment registration form Treatment intent (palliative or curative)
After completed first treatment Date of first initiation of treatment
Only completed in chemotherapy-treated patients Clinical trial participation (yes, no,  and specified)
For each cycle of combination chemotherapy, if given:
Date of initiation, type, and dose
Classification of bone marrow response
Date of evaluation
Transplantation  (yes/no)
if yes, date of transplantation
Type of transplantation (myeloablative, reduced intensity conditioning, 
or autologous)
Relapse registration form Date of relapse
At relapse Treatment intent (palliative or curative)
if chemotherapy is initiated at relapse,  
the registration form is filed after completion
For each cycle of combination chemotherapy, if given: 
Date of initiation, type, and dose
Classification of bone marrow response
Date of evaluation
(Continued)
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Table 1 (Continued)
Registration form and time of registration Variables
Acute leukemia (AML, ALL)  
Follow-up registration form
Status (dead/alive)
At death or termination of follow-up as an outpatient Date of death or end of follow-up
Cause of death
Myelodysplastic syndrome (MDS)
Registration form Name, civil registration (CPR) number, and demographic data
At diagnosis MDS diagnosis according to wHO (2008)/iCD-10
Cytopenia
 Anemia (,6.2 mmol/L) (Y/N)
 Thrombocytopenia (,100×109/L) (Y/N)
 Neutropenia (,1.8 mia/L) (Y/N)
Results of cytogenetic evaluation
 Good Risk (-Y, del5q, del20q)
 Intermediate risk (not classified as good risk or poor risk)
  Poor risk (chromosome 7 aberrations or complex karyotype  
[.3 changes])
Blast percentage in the blood and bone marrow
Prior hematological or disease or cancer (specified, if present)
Primary treatment
Treatment registration form  Transfusion (Y/N)
 Erythropoietin (Y/N)
 Granulocyte colony-stimulating factors (Y/N)
 iron-chelating agents (Y/N)
 Hydroxyurea (Y/N)
 Demethylating agents (Azacytidin®) (Y/N)
 Remission-induction-like chemotherapy (Y/N)
 immunotherapy (Y/N)
 Lenalidomide? (Y/N)
 Others (Y/N)
Progression to acute leukemia (Y/N)
 if yes, date of progression
Clinical trial participation (Y/N)
Allogeneic stem cell transplantation (Y/N)
 if yes (date and type of transplantation)
Follow-up registration form Status (dead/alive)
At death or termination of follow-up as an outpatient Date of death or end of follow-up
if alive, name of hospital department continuing treatment and follow-up
Note: Adapted with permission of Dove Medical Press Ltd., from Data quality in the Danish National Acute Leukemia Registry: a hematological data resource, Østgård L, 
Nørgaard J, Severinsen M, et al, Clin Epidemiol, 2013;5:335–344,8 Copyright © 2009; permission conveyed through Copyright Clearance Center, inc.
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CPR, civil registration number; ICD, International Classification of Diseases; FISH, 
fluorescence in situ hybridization; WHO, World Health Organization; WHO PS, World Health Organization performance status score; Y, yes; N, no; FAB, French-American-
British.
(Table 1). Depending on treatment schedule and clinical 
course, data on more than 150 variables (patient- and leuke-
mia-related, treatment- and outcome-related) can be recorded 
for each patient. The first form is completed at diagnosis. 
To optimize data quality, the clinical cytogeneticist enters 
cytogenetic details obtained at diagnosis. A second form is 
completed following first-line treatment in chemotherapy-
treated patients and includes information about allogeneic 
transplantation performed in first CR. A third form is com-
pleted in case of relapse. A fourth form is completed at death 
or termination of clinical follow-up.
For MDS patients, up to three registration forms are 
completed: a registration form at diagnosis, a treatment form, 
and a form at death or termination of follow-up.
We recently performed a validation study of the quality 
of AML registrations in the DNLR.8 In that study, the cover-
age of the DNLR was found to be 99.6% (95% confidence 
interval [CI] 99.3–99.8) with the DNRP used as a reference. 
We validated DNLR information in a random sample of 260 
patients, and found completeness to exceed 90% in 23 out of 
30 selected variables. The positive predictive values (PPVs) 
were higher than 95% for 23 variables, and higher than 90% 
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Table 2 Completeness and PPvs of 30 variables from the DNLR
Variable Number of correctly  
coded records/ 
number of relevant  
records reviewed
Completeness (%)  
(95% CI)
PPV (%)  
(95% CI)
Diagnosis 244/245 100 (99.0–100) 99.6 (98.1–100)
Time of diagnosis (±24 hours) 219/245 100 (99.0–100) 89.4 (85.1–92.8)
Time of diagnosis (±6 days) 236/245 96.3 (93.4–98.2)
Cytogenetic result 220/231 99.6 (98.0–99.9) 95.2 (91.9–97.4)
Cytogenetic result, specified 224/231 99.1 (97.3–99.8) 97.0 (94.4–98.6)
Prior hematological disease 231/240 98.0 (96.6–99.2) 96.3 (93.2–98.1)
Prior hematological disease, specified 42/44 83.0 (71.3–91.3) 95.5 (86.2–99.0)
Prior cancer, other than hematological 182/186 75.9 (70.3–80.1) 97.8 (95.0–99.3)
  Missing categorized as no prior cancer 238/245 100 (99.0–100) 97.1 (94.5–98.7)
Prior cancer, specified 16/17 60.7 (42.3–77.0) 94.1 (75.7–99.4)
Prior chemotherapy 234/244 100 (99.0–100) 95.9 (92.9–97.9)
Prior radiotherapy 239/244 100 (99.0–100) 98.0 (95.6–99.2)
wHO PS 236/241 100 (99.0–100) 97.9 (95.5–99.2)
Extramedullary leukemia 217/230 96.2 (93.2–98.1) 94.3 (90.8–96.8)
Extramedullary leukemia, specified 27/29 72.5 (57.5–84.4) 93.1 (79.7–98.6)
white blood cell count (wBC) (1×109/L) 218/232 97.9 (95.4–99.2) 94.0 (90.3–96.5)
Platelet count (1×109/L) 211/231 97.5 (94.9–98.9) 91.3 (87.2–94.5)
Lactate dehydrogenase (U/L) 157/161 67.9 (61.8–73.6) 97.5 (94.2–99.2)
weight 216/216 90.4 (86.2–93.6) 100 (98.8–100)
Height 214/215 90.0 (85.7–93.2) 99.5 (97.8–99.9)
Curative intent? 229/233 97.5 (94.9–98.9) 98.3 (96.0–99.4)
Protocol participation? 116/119 94.4 (89.4–97.5) 97.5 (93.4–99.3)
Time of initiated treatment 205/206 98.6 (96.2–99.6) 99.5 (97.8–99.8)
First course of induction chemotherapy,  
specified
194/204 97.1 (94.2–98.8) 95.1 (91.5–97.5)
Dose of first course of induction  
chemotherapy, specified
203/204 97.1 (94.2–98.8) 99.5 (97.7–99.9)
Bone marrow response, after first course of  
chemotherapy
202/205 97.1 (94.2–98.8) 98.5 (96.1–99.6)
Second course of induction chemotherapy, specified 195/202 96.2 (92.9–98.2) 96.5 (93.3–98.4)
Dose of second course of induction  
chemotherapy, specified
201/203 96.7 (93.6–98.5) 99.0 (96.9–99.8)
Bone marrow response, after second course of  
chemotherapy
197/200 95.2 (91.7–97.5) 98.5 (96.1–99.6)
Relapse? (if yes, date specified) 157/161 94.7 (90.6–97.3) 97.5 (94.2–99.2)
Extramedullary leukemia at relapse? 53/55 88.7 (79.1–94.8) 96.4 (88.9–99.2)
Cause of death 136/146 81.1 (74.9–86.3) 93.2 (88.2–96.4)
Note: Adapted with permission of Dove Medical Press Ltd., from Data quality in the Danish National Acute Leukemia Registry: a hematological data resource, Østgård L, 
Nørgaard J, Severinsen M, et al, Clin Epidemiol, 2013;5:335–344,8 Copyright © 2009; permission conveyed through Copyright Clearance Center, inc.
Abbreviations: PPv, positive predictive value; DNLR, Danish National Acute Leukemia Registry; wHO PS, world Health Organization performance status score; Ci, 
confidence interval.
for 29 of 30 variables (Table 2). The quality of data registered 
on ALL patients is not expected to vary, since the variables 
are identical and the same physicians are entering data. The 
coverage of the MDS registry is estimated to be 90%, and a 
validation study of the individual variables has been planned 
for MDS data to be performed prior to use of data for research 
purposes.
Follow-up
In leukemia patients, treatment responses are registered accord-
ing to international guidelines.9 For patients achieving CR, 
relapses are registered. For all patients, date of death or end 
of follow-up due to other causes is registered in the DNLR. 
Data are cross-linked to the Danish Civil Registration System 
to ensure accurate information on vital status. Based on these 
variables, leukemia-free and overall survival can be calculated. 
Since both ALL and AML are aggressive cancers and MDS 
patients in general are older, a high proportion of patients die 
within 1–5 years of follow-up. (Overall survival rates for AML 
and ALL patients are shown in Figure 1.) By December 2013, 
the DNLR consisted of data on 3,055 AML patients (exclud-
ing acute promyelocytic leukemia). In September 2014, these 
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patients had a combined follow-up time of 5,296 years and a 
mean follow-up time of 188 days; 512 days in intensive therapy 
patients (interquartile range [IQR]: 179–1,374) and 64 days in 
palliative intent patients (IQR: 19–184).
Examples of research
The DNLR has been used for various studies in which it 
has been merged with local databases (transplantation and 
clinical trial office databases) and national registries (the 
Danish Civil Registration System, DNRP, the Danish Cancer 
Registry).
In one study, the registry was used to investigate the impact 
of patient and disease characteristics on TTT and to assess the 
effect of TTT on treatment response (CR) and survival.10
In a second study, data were used to examine how treat-
ment intent varies by comorbidity and functional status (World 
Health Organization performance status score [WHO PS]) and 
to determine the prognostic impact of comorbidity and PS on 
achievement of CR, early death, and long-term mortality.11
In a third study, data were used to estimate frequencies of 
therapy-related and secondary AML (MDS and non-MDS) 
overall and over time; they were also used to describe dif-
ferences in characteristics, and outcome between intensively 
treated secondary and therapy-related AML (depending on 
prior hematological disease or cytotoxic therapy) and de 
novo AML patients.12
In a fourth study, the registry was used to estimate the 
patient accrual rates of clinical AML trials in Denmark, to 
describe the difference in patient and disease characteristics 
as well as outcome between patients treated according to 
clinical trials and those treated outside clinical trials.13
In an ongoing study, researchers are investigating the 
impact of body mass index (BMI) on prognosis. Data on 
smoking and alcohol consumption are obtained from medical 
records and will be used to investigate the impact of lifestyle 
factors on outcome.
Finally, the importance of the quality of CR with recon-
stitution of bone marrow function is being investigated using 
data from the National Danish Transfusion Database.
ALL and MDS data have not yet been used for research, 
as the number of patients is relatively small and the follow-
up time is short. A Nordic collaboration aims to merge data 
between national MDS registries, thereby expanding the 
study population.
Conclusion
The DNLR includes patient and disease characteristics, as 
well as outcome data on MDS and acute leukemia patients. 
The completeness and PPVs of the data are high, and the 
registry captures more than 99.5% of AML patients. So far, 
these high-quality data have been used for large nationwide 
prognostic studies of AML. Within the next 5 years, the fol-
low-up time for MDS and ALL patients will allow these data 
to be explored. In conclusion, the DNLR has shown to be a 
valuable resource for clinical research of acute leukemia.
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